


# LIVERFASt™

Fibrosis • Activity • Steatosis

AN INNOVATIVE  
DIAGNOSTIC AND  
SCREENING TOOL  
FOR A  
COMPLETE  
LIVER EVALUATION



## Simple and Convenient



Physician prescribes  
**LIVERFAST™**  
for the patient



Lab analyses  
10 biomarkers from  
1 blood sample




Biomarker results  
inputted into Fibronostics  
AI platform




Results are  
available  
immediately

## LIVERFAST Provides a Full Liver Evaluation for Multiple Etiologies


**Hepatitis B  
(HBV)**




**Hepatitis C  
(HCV)**



**Non-Alcoholic  
Fatty Liver Disease  
(NAFLD)**



**Alcoholic Liver Disease  
(ALD)**



## Distinctive Staging of Three Lesions

### FIBROSIS

SCORE	STAGE	INTERPRETATION
0.75 - 1.00	F4	Severe fibrosis (Cirrhosis)
0.59 - 0.74	F3	Significant fibrosis
0.49 - 0.58	F2	Moderate fibrosis
0.28 - 0.48	F1	Minimal fibrosis
0.00 - 0.27	F0	No fibrosis

### ACTIVITY

SCORE	STAGE	INTERPRETATION
0.73 - 1.00	A4	Severe activity
0.63 - 0.72	A3	Significant activity
0.53 - 0.62	A2	Moderate activity
0.30 - 0.52	A1	Minimal activity
0.00 - 0.29	A0	No activity

### STEATOSIS

SCORE	STAGE	INTERPRETATION
0.69 - 1.00	S3	Severe steatosis (>32%)
0.57 - 0.68	S2	Moderate steatosis (6-32%)
0.38 - 0.56	S1	Minimal steatosis (1-5%)
0.00 - 0.37	S0	No steatosis (<1%)


## Distinctive Staging of Three Lesions

LIVERFAST™ provides a complete liver evaluation with the staging of fibrosis, activity, and steatosis

	LIVERFAST™	APRI	FIB-4	ELF	NIS4	ProC3	Fibasure
Specific for Fibrosis	✓	✓	✓	✓	✗ (MIX F.A.S)	✗ (MIX F.S)	✓
Specific for Activity	✓	✗	✗	✗	✗	✗	✗ (MIX A.S)
Specific for Steatosis	✓	✗	✗	✗	✗	✗	✓
NASH Staging	✓	✗	✗	✗	✓ Only severe NASH	✓ Only NASH Cirrhosis	✓
No. of Biomarkers	10	2	3	3	4	1	10
Bias in fibrosis assesment	✗	✓	✓	✓	✓	✓	✓

(TE = Transient Elastography, MRI = Magnetic Resonance Imaging, APRI = AST-to-Platelet Ratio Index, ELF = Enhanced Liver Fibrosis, FIB-4 = Fibrosis-4 index)

## Non-Invasive and Equivalent to 25mm Biopsy



**There was no significant difference between biopsy and fibrosis score estimates regardless of disease or virological response<sup>5</sup>**

Ave: Average mean for the combined group of studies  
NR: Non-responders  
R: HBV responders  
SVR: HCV sustained virological responders

# SAMPLE RESULT SHEET




PATIENT NAME:	DATE OF BIRTH:	GENDER:	HEIGHT:	WEIGHT:	BMI:
NAME OF PHYSICIAN:			DATE OF TEST TAKEN:		

## BIOMARKER RESULTS

Sample Date	February 04, 2021				
alpha-2-Macroglobulin	267 mg/dL	ALT	56 IU/L		
Haptoglobin	174 mg/dL	AST	62 IU/L		
Apolipoprotein A1	153 mg/dL	Fasting Glucose	124 mg/dL		
Total Bilirubin	0.6 mg/dL	Total Cholesterol	120 mg/dL		
GGT	227 IU/L	Triglycerides	120 mg/dL		


## SCORES

### FIBROSIS




**F2**  
Moderate Fibrosis  
0.58

### ACTIVITY



**A1**  
Minimal Activity  
0.43

### STEATOSIS



**S3**  
Severe Steatosis  
0.83

#### FIBROSIS:

Liver fibrosis represents scarring of the liver. Scarring of the liver is due to reaction from viral infections, fat and/or alcohol.

#### ACTIVITY:

Liver activity represents inflammation of the liver. Inflammation of the liver is due to reaction from viral infections, fat and/or alcohol.

#### STEATOSIS:

Liver steatosis is the accumulation of fat in the liver. Liver steatosis is commonly due to metabolic anomalies (e.g. Dyslipidemia, diabetes, overweight/obesity) and/or alcohol.

## INTERPRETATION

- Your result for the SAF score is S3-A1-F2.
- This score indicates that you have severe steatosis, minimal inflammatory activity and moderate fibrosis.
- Consult your physician for further evaluation.

#### PRECAUTIONS:

- The reliability of results is dependent on compliance with the preanalytical and analytical conditions recommended by Fibronostics.
- The test must be deferred for acute hemolysis, acute hepatitis, acute inflammation, extra hepatic cholestasis.
- The advice of a specialist must be sought for interpretation in chronic hemolysis and Gilbert's syndrome.
- The test interpretation is not validated for liver transplant patients.
- Isolated extreme values of any of the biomarker results should lead to caution in interpreting the results.
- In the case of discordance between a biopsy result and a test, it is recommended to seek the advice of a specialist.
- The causes of these discordances could be due to a flaw of the test or to a flaw in the biopsy, i.e. a liver biopsy has a 33% variability rate for one fibrosis stage.
- The fibrosis score is interpretable for chronic hepatitis B, chronic hepatitis C, alcoholic steatosis and non-alcoholic steatosis.
- The activity score is interpretable for chronic hepatitis B and chronic hepatitis C.

CLIA# 10D2190357

# STRONG SCIENTIFIC EXPERTISE

Widely used, researched and validated patented test

# 285

STUDIES  
PUBLISHED

by

# 1133

AUTHORS

in

# 89

JOURNALS

## OUR OTHER TEST AVAILABLE

### LIVERFAST<sup>™</sup> select

**FIBRONOSTICS LIVERFAST select SAMPLE RESULT SHEET**

PATIENT NAME: DATE OF BIRTH: SEX: HEIGHT: WEIGHT: BMI: AGE:

NAME OF PHYSICIAN: DATE OF TEST ORDER:

**BIOMARKER RESULTS**

Service Date:	10/01/2019		
Total Bilirubin	0.2 mg/dL	Total Cholesterol	6.8 mmol/L
GGT	65 U/L	Triglycerides	6.2 mmol/L
ALT	28 U/L		
AST	24 U/L		

**SCORES**

**YOUR RISK FOR FATTY LIVER IS HIGH**

**INTERPRETATION**

The test is preliminary risk score based on the biomarker results above.

Please consult with your physician or other qualified healthcare professional for further evaluation. If you have concerns or questions about your health, you should always consult your local medical practitioner.

**DISCLAIMER**

This test is only meant for risk evaluation.  
For a full liver diagnosis, it is recommended to perform the complete version of LiverFast.

Please note that the risk for steatosis is high as it is directly correlated with obesity.



Fibronostics specializes in algorithm-based  
non-invasive diagnostic solutions.  
For more information, please visit

**[www.fibronostics.com](http://www.fibronostics.com)**

3452 Lake Lynda Drive, Bldg 100, Suite 151,  
Orlando, Florida, 32817

Contact Us  
**[service@fibronostics.com](mailto:service@fibronostics.com) | 1-888-552-1603**

LIVERFAST Proprietary CPT Code 0166U

#### References:

1. "Hepatitis B." World Health Organization, <https://www.who.int/news-room/fact-sheets/detail/hepatitis-b>
2. "Hepatitis C." World Health Organization, <https://www.who.int/news-room/fact-sheets/detail/hepatitis-c>
3. Younossi, Z. M. et al. "Global epidemiology of nonalcoholic fatty liver disease — meta-analytic assessment of prevalence, incidence, and outcomes." *Hepatology*. 2016; 64: 73-84
4. Liangpunsakul, S. et al. "Alcoholic Liver Disease in Asia, Europe, and North America." *Gastroenterology*. 2016 June; 150(8): 1786-1797
5. Poynard, T. et al. "Biomarkers of liver injury for hepatitis clinical trials: a meta-analysis of longitudinal studies." *Antiviral Therapy*. 2010; 15: 617-631